Metropolis Healthcare Q1 FY27 Earnings Call — Analysis (NSE: METROPOLIS)
Metropolis targets expanding EBITDA margins to 27%-28% over the next 2-3 years while guiding for 14%-15% medium-term organic revenue growth driven by network utilization, specialty mix, and 100 planned basic radiology mini-hubs.
Result quality: strong — Margin expansion. Management sentiment: optimistic.
The take
FY26 Revenue ₹1,646 Cr ( +23.6% YoY ) . New guidance — FY28 organic revenue growth 14% to 15% . New story: Operating Leverage via Network Densification .
Results
FY26 revenue closed at ₹1,646 Cr with EBITDA margin at 24.4% (organic margin at 25.9% excluding Core Diagnostics dilution), while Q1FY27 delivered 17% YoY growth.
Financial highlights
| Metric | Value | Change | Basis |
|---|---|---|---|
| Revenue | ₹1,646 Cr | +23.6% | yoy · FY26 · FY26 annual revenue |
| EBITDA Margin | 24.4% | none · FY26 · Reported EBITDA margin including Core Diagnostics acquisition | |
| Organic EBITDA Margin | 25.9% | none · FY26 · Excluding initial dilution from Core Diagnostics | |
| Revenue Growth | 17% | +17% | yoy · Q1FY27 · Reported Q1 growth YoY |
Guidance
Management guided for 14%-15% medium-term organic revenue growth without price hikes, aiming to expand EBITDA margins to 27%-28% and scale TruHealth wellness packages to 25% of revenue.
What management committed to
- Metropolis Healthcare Limited targets improving EBITDA margin from 24.4% to 27% to 28% over the next 2 to 3 years. — 27% to 28%, FY29
- Metropolis Healthcare Limited guides for medium-term baseline organic revenue growth of 14% to 15% without price increases. — 14% to 15%, FY28
- Metropolis Healthcare Limited plans to take the collection center-to-lab ratio from 1:24 to 1:35 in the next couple of years. — 1:35, FY29
- Metropolis Healthcare Limited aims to increase TruHealth package revenue share from 18%-20% to 25%. — 25%, FY29
- Metropolis Healthcare Limited plans to set up 100 basic radiology mini-hubs (50 upgrades, 50 new) in the next couple of years with ~₹35-40 lakhs capex per center. — 100 mini hubs, FY29
- Metropolis Healthcare Limited targets bringing Core Diagnostics EBITDA margin close to company-level EBITDA margins (20%-25%) by year 3 post-acquisition. — 20%-25%, FY28
- Metropolis Healthcare Limited will not allocate domestic capital to fund international lab operations.
- Metropolis Healthcare Limited will not pursue capital-intensive advanced radiology (CT/MRI) as a core financial strategy.
Key themes
Network densification, specialty test expansion, margin expansion
How the narrative shifted
- Operating Leverage via Network Densification: Management emphasizes that following the heavy lab additions between 2021-2025, FY26-FY29 will harvest fixed cost leverage by expanding center density per lab from 24 to 35 without adding new hub labs.
- Specialty and Genomics Mix Expansion: Higher-complexity testing (oncology, neurology, genomics) provides pricing uniformity across metro and tier-2/3 towns, widening the competitive moat against hospital and standalone labs.
- Selective Asset-Light Radiology Mini-Hubs: Adding low-capex ultrasound, ECG, and X-ray modalities to 100 existing/new centers will capture corporate wellness checkups and optimize afternoon real estate utilization.
- Disciplined M&A Playbook and Turnarounds: Metropolis is avoiding high-multiple aggregator bidding wars, focusing on turning around break-even, high-skill specialty assets like Core Diagnostics into 20%-25% EBITDA contributors.
- Capital Allocation Discipline: Strict adherence to self-funded international growth, single-digit working capital targets, dividend payouts of ~22% PAT, and avoidance of heavy illness-imaging CT/MRI capex.
Operational commentary
- Network infrastructure currently spans 209 laboratories, 5,000+ total collection centers (700-750 company-owned, remainder franchised) across 750 Indian towns and 5 international markets.
- Targeting an increase in the collection center-to-lab ratio from 1:24 currently to 1:35 over the next 2-3 years, adding 250-300 centers quarterly.
- Planning rollout of 100 basic radiology mini-hubs (50 upgrades of existing company centers and 50 new centers) equipped with ultrasound, X-ray, TMT, and 2D echo at ₹0.35 Cr-₹0.40 Cr capex per unit.
- Integrated Core Diagnostics acquisition to bolster oncology testing menu (adding ~350 tests and 2,000 oncologists), achieving high single-digit EBITDA in year one with target to reach company-average margins by year three.
- Added approximately 380-400 specialized tests over the past 15 months, including blood-based Alzheimer's risk biomarkers and hereditary cancer gene panels.
- Deployed NovaSeq X System for high-throughput genomics, operating 2 CAP-accredited genomics facilities (West and North).
- Digital channel accounts for 25% of revenue, with home collection covering 2,200+ pin codes and Insta60 60-minute phlebotomy pilot launched in Mumbai and Chennai.
Analyst Q&A
Q. What is the longer-term operating margin profile and investment cycle outlook?
Management explained that FY26 to FY29 represents a phase of reaping operating leverage from prior lab investments (FY21-FY25), targeting 27%-28% EBITDA margins before requiring another capex cycle.
Q. What is the capex and revenue contribution expected from the 100 planned radiology mini-hubs?
Estimated capex is ₹35-40 lakhs per center with an expected 2x-3x productivity boost, beginning with 50 pilot upgrades in year one before rolling out the remaining 50 centers.
Q. Will Metropolis enter large-scale advanced radiology centers (CT/MRI) across its network?
Management clarified that advanced radiology is not a core strategy due to dilutive ROCE and governance concerns in illness-driven imaging, though 1-2 pilot centers may be evaluated in preventive wellness.
Q. How will regional mix evolve, particularly for North and East India?
North India contribution is expected to increase from 18% toward 25% due to Core Diagnostics synergies, while East India remains under-invested until dedicated capital is allocated.
Research and educational content only. Not investment advice.